Search
Now showing items 1-10 of 10
Specialised early intervention for recent-onset psychosis
(2022-03)
Specialised early intervention (SEI) services have seen significant investment and expansion in the UK, aiming to improve long-term outcomes for psychotic disorders. This commentary discusses a recent Cochrane review that ...
Automated virtual reality therapy to treat agoraphobic avoidance and distress in patients with psychosis (gameChange): a multicentre, parallel-group, single-blind, randomised, controlled trial in England with mediation and moderation analyses
(2022-04)
Automated delivery of psychological therapy using immersive technologies such as virtual reality (VR) might greatly increase the availability of effective help for patients. We aimed to evaluate the efficacy of an automated ...
The service user experience of SlowMo therapy: A co-produced thematic analysis of service users' subjective experience
(2022-04)
Objectives: SlowMo is the first blended digital therapy for paranoia, showing significant small-moderate reductions in paranoia in a recent large-scale randomized controlled trial (RCT). This study explored the subjective ...
The psychological journey of weight gain in psychosis
(2022-02)
Rapid weight gain is common with antipsychotic medication. Lost confidence, low mood and medication non-adherence often follow. Yet, the dynamic interactions between the physical and psychological consequences of weight ...
SlowMo therapy, a new digital blended therapy for fear of harm from others: An account of therapy personalisation within a targeted intervention
(2022-01)
Objectives: SlowMo therapy is a pioneering blended digital
therapy for paranoia, augmenting face-to-face therapy with
an interactive ‘webapp’ and a mobile app. A recent largescale trial demonstrated small–moderate effects ...
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)
After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ...
A family perspective on parental psychosis: An interpretative phenomenological analysis study
(2022-11)
Objectives: While one third of people with a psychotic
disorder are a parent, there has been little research to date
examining the consequences of this from a whole family
perspective. This study investigates families ...
The Needs and Experiences of Parents with Psychosis: A Qualitative Interview Study
(2022-09)
Over a third of individuals diagnosed with a psychotic disorder are also a parent. The symptoms of psychosis and side effects of antipsychotic medication can impact on parents’ awareness of the needs of their children and, ...
The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis
(2022-09)
A range of studies suggest that a proportion of psychosis may have an autoimmune basis, but this has not translated through into clinical practice—there is no biochemical test able to accurately identify psychosis resulting ...
Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders?
(2022-08)
Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety ...